Open AccessFuture perspectives on the treatment of hepatocellular carcinoma with cisplatin
Author(s) -
Toru Ishikawa
Publication year - 2009
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v1.i1.8
Subject(s) - medicine , hepatocellular carcinoma , cisplatin , malignancy , liver transplantation , genitourinary system , chemotherapy , oncology , incidence (geometry) , carcinoma , gastroenterology , transplantation , physics , optics
Hepatocellular carcinoma (HCC) is the commonest primary liver malignancy. Its incidence is increasing worldwide. Surgery, including transplantation resection, is currently the most effective treatment for HCC. However, recurrence rates are high and long-term survival is poor. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. Cisplatin (CDDP) is a key drug for the standard regimens of various cancers in the respiratory, digestive and genitourinary organs. Recently, several encouraging results have been shown in using CDDP in the treatment of advanced HCC patients. This review examines current knowledge regarding the chemotherapeutic potential of CDDP.